criteria included non-anomalous vertex singleton gestation and no prior history of CD. Rates of CD, and maternal and neonatal morbidity rates were calculated. Labor data was collected. RESULTS: There were 4976 deliveries in the study period, 525 underwent a primary CD for arrest disorder; 298 prior to 2014 and 227 after 2014.
The primary cesarean delivery rate did not change during the study period (12.4% in 2011 V,16,4% in 2017; P trend 0.17) .
In patients undergoing CD for arrest of dilation (n¼389), the median maximum cervical dilation was at 6.0 cm before 2014 and 7.0 cm after 2014 (P¼0.017). In these women, there was an increase in the time spent at last dilation: 6.1 hours V. 7.0 hours before and after 2014 respectively (P¼0.008). There was a significant decrease in the frequency of patients diagnosed with the arrest of dilation at <6 cm, 16.4% before 2014 and 9.7% after 2014 (P<0.001). The composite maternal and neonatal outcomes were not significantly changed between both groups.
There were 136 cesarean deliveries performed for arrest of descent. Pushing times slightly increased for nulliparas (3.5 hours to 4.2 hours before and after 2014 respectively (P¼0.07)) and for multiparous (2.9 hours to 3.8 hours before and after 2014 respectively (P¼0.50)). In patients who had a CD for arrest of descent, rate of composite maternal morbidity significantly increased from 50% to 75% (P¼0.02) with no change in the composite neonatal outcomes. CONCLUSION: Despite significant changes in labor management after the publication of the Obstetric Care Consensus statement, our primary cesarean delivery rate was not reduced and we noticed an increase in maternal morbidity in patients who had arrest of descent. A randomized controlled trial is needed to evaluate the effect of these guidelines nationally.
670 Mesenchymal stem cells suppress inflammatory cytokines in lipopolysaccharide exposed preterm human pregnant myometrial cells Arunmani Mani, John W. Hotra, Sean C. Blackwell, Jerrie S. Refuerzo
McGovern Medical School at The University of Texas Health Science Center at Houston, Houston, TX OBJECTIVE: Bone marrow derived mesenchymal stem cells (MSC) exert immunosuppressive effects that have broadened the treatment of inflammatory conditions such as myocardial infraction, multiple sclerosis and diabetes. Intrauterine infection associated with inflammation is a cause of preterm birth (PTB). Lipopolysaccharide (LPS)-based models of PTB increase levels of pro-inflammatory cytokine IL-6. MSC exert suppression through anti-inflammatory cytokine TGF-b1. We have previously reported that MSC can suppress the inflammatory response in term human myometrial (MYO) cells (AJOG 689) The objective of this study was to determine the cytokine response in human pregnant preterm myometrial cells exposed to LPS and treated with MSC. STUDY DESIGN: Preterm (PT) and term (T) human myometrial tissues were obtained at the time of cesarean delivery. The LPS model of PTB involved exposing MYO cells to 5 mg/ml LPS for 4 h followed by 1 mg/ml LPS for 24 h. These MYO cells were then treated with MSC for 24 h. Cell culture supernatants were collected to measure IL-6 and TGF-b1 levels by ELISA. Comparisons between groups was performed using two way ANOVA. RESULTS: PT cells were obtained from 4 women 34-35 weeks pregnant and T cells from 3 women 38-39 weeks pregnant. In unexposed MYO cells, basal levels of IL-6 were significantly higher in PT than T cells, (PT MYO: 1267.3 AE 435.7 vs. T MYO: 203.1 AE 90.9, pg/ml, p<0.01, Fig 1) . When exposed to LPS, PT cells expressed significantly higher IL-6 levels compared to unexposed PT cells, (LPS: 3335.8 AE 280.4 vs. PT MYO: 1267.3 AE 435.7 pg/ml, p< 0.01). Treatment with MSC significantly suppressed IL-6 expression in PT cells exposed to LPS (LPS 3335.8 AE 280.4 vs LPS+MSC: 525.2 AE 78.3 pg/ml, p<0.01). MSC treatment resulted in significantly increased levels of TGF-b1 with and without exposure to LPS, (LPS+MSC: 884.7 AE 179.4 vs. MSC: 881.2 AE139.0 vs. PT MYO: 40.8 AE 3.5 pg/ml, p<0.01, Fig 2) . Suppressive effects of MSC was significantly higher in PT than in T cells. CONCLUSION: In our LPS model of PTB, MSC treatment resulted in a 6-fold suppression in inflammatory cytokine IL-6 and a 20-fold increase in anti-inflammatory cytokine TGF-b1. Therefore, these immunosuppressive potential of MSC provide innovative opportunities for cell mediated therapeutics in inflammation-based PTB. OBJECTIVE: The purpose of the study was to compare the efficacy and safety of induction of labor with misoprostol amongst primiparas, multiparas and grandmultiparas. STUDY DESIGN: We conducted a retrospective cohort study of all women who underwent induction of labor with prostaglandin E1. Inclusion criteria included term singleton pregnancies. Exclusion criteria included multiple gestation, history of Cesarean delivery, and fetuses with intrauterine growth restrictions or known anomalies. All women received 50 micrograms misoprostol orally and this dose was repeated every four hours if active labor did not develop, up to a maximal dose of 300 micrograms. We divided the women into three groups: primiparas, multiparas (defined as parity of 1-4), and grandmultiparas (defined as para 5 and above). Primary outcome was mode of delivery and secondary outcome was neonatal 5 minute Apgar and umbilical cord (UA) pH. We defined efficiency as the duration from administration of the first cytotec dose until delivery. We also collected data on maternal and neonatal complications. RESULTS: Between January-December 2017, 1713 women underwent induction of labor: 523 were primiparas, 656 were multiparas and 534 were grandmultiparas. Four hundred and seventy-nine (91.6%) primiparas delivered vaginally as did 640 (97.6%) multiparas and 521(97.6%) grandmultiparas. Induction to delivery interval was significantly longer in primiparas (mean: 29.7 hours; 95% CI: 27.8-31.7 hours), and there was no significant difference between multiparas (mean: 18.6 hours; 95% CI: 17.3-20.0 hours) and grandmultiparas (mean: 18.6 hours; 95% CI: 17.0 -20.1 hours). There were no cases of uterine rupture, and the rates of postpartum hemorrhage and endometritis were similar among the three groups The rate of 5 minute Apgar score below 7 and UA pH<7.1 were not significantly different between the groups. CONCLUSION: Using misoprostol for labor induction is efficient and safe in primiparas, multiparas, and grandmultiparas. OBJECTIVE: To evaluate the association of the length of a passive second stage on complications of labor STUDY DESIGN: The pregnancy, labor, and delivery outcomes for Certified Nurse Midwife patients at a tertiary care hospital have been prospectively entered into a quality assurance database since 2006. These women were all considered appropriate for midwifery care prenatally and thus represent a relatively low-risk population. Term pregnancies without an indication for cesarean delivery on presentation to labor and delivery were eligible for analysis. It is the standard practice of the CNM group to encourage women with
